Buprenorphine can cause physical dependence, meaning your body adapts to it and you’ll experience withdrawal if you stop abruptly. But physical dependence and addiction are not the same thing. Buprenorphine’s unique pharmacology makes it far less likely to produce the compulsive, out-of-control drug-seeking behavior that defines addiction compared to full opioids like oxycodone, heroin, or fentanyl.
Understanding the distinction matters because fear of “trading one addiction for another” is one of the most common reasons people avoid or quit a medication that dramatically reduces overdose deaths. Here’s what the science actually shows.
How Buprenorphine Differs From Other Opioids
Buprenorphine is a partial agonist at the brain’s main opioid receptor. That means it activates the receptor only partway, unlike full agonists such as morphine, fentanyl, or heroin, which activate it completely. Think of it like a dimmer switch turned halfway up versus a light switch flipped fully on. This partial activation is enough to ease withdrawal symptoms and reduce cravings, but it produces significantly less euphoria.
The drug also binds very tightly to opioid receptors and releases slowly. This tight grip means that if someone takes a full opioid like heroin on top of buprenorphine, the heroin can’t fully activate the receptor. Buprenorphine essentially blocks other opioids from producing a high, which is one reason it works so well as a treatment medication.
Perhaps the most important safety feature is something called the ceiling effect. As the dose increases, buprenorphine’s effects plateau rather than continuing to climb. In clinical testing, single doses up to 70 times the recommended analgesic dose were well tolerated in non-dependent volunteers. Respiratory depression, the cause of death in opioid overdoses, also plateaus. This makes lethal overdose from buprenorphine alone far less likely than from full agonist opioids.
Physical Dependence vs. Addiction
These two terms are often used interchangeably, but they describe fundamentally different processes. Physical dependence is your body’s predictable adaptation to a substance taken regularly. It happens with blood pressure medications, antidepressants, and corticosteroids too. If you stop suddenly, you get withdrawal symptoms. That’s biology, not addiction.
Addiction, now formally called “opioid use disorder” in psychiatric diagnosis, involves loss of control over drug use despite harmful consequences. It’s the compulsive craving, the inability to stop even when your life is falling apart, the escalating doses chasing a high. You can have physical dependence without addiction, and you can have addiction without visible physical withdrawal. People don’t suffer obvious physical withdrawal from cocaine, for example, but cocaine addiction is severe.
Buprenorphine will cause physical dependence if taken regularly. You will experience withdrawal symptoms if you stop. But the withdrawal is milder than with heroin, fentanyl, or methadone because of buprenorphine’s slow release from receptors. Symptoms resolve more quickly, and the experience is generally less intense. This is a meaningful difference for people who eventually want to taper off.
How Often Is Buprenorphine Misused?
Buprenorphine misuse does happen, but the pattern looks different from typical opioid abuse. Among patients receiving buprenorphine for opioid use disorder treatment, diversion rates peak around 4.7 to 4.8%. When people do obtain buprenorphine outside a prescription, research consistently finds that most use it to manage withdrawal symptoms or reduce heroin consumption rather than to get high. One study found a significant relationship between more frequent non-prescribed buprenorphine use and lower frequency of heroin and fentanyl use.
Deaths involving buprenorphine are rare, and when they do occur, they almost always involve other substances, particularly benzodiazepines or alcohol. A CDC-supported review noted that buprenorphine-related deaths are far fewer compared to deaths involving other prescribed opioids, and specifically chose not to examine overdose rates in detail because of buprenorphine’s “well-established low risk.”
Some formulations combine buprenorphine with naloxone, an opioid blocker. When taken as directed under the tongue, the naloxone has almost no effect because less than 10% is absorbed that way. But if someone dissolves the tablet and injects it, the naloxone activates fully, blocks opioid receptors, and triggers immediate withdrawal. This built-in safeguard discourages intravenous misuse.
What Happens When You Stop
Tapering off buprenorphine is possible, but relapse rates are high regardless of how the taper is structured. In a large randomized trial comparing a 7-day taper to a 28-day taper, about 44% of the short-taper group and 30% of the long-taper group tested opioid-free at the end of the taper itself. But by three months later, those numbers had converged and dropped sharply: only about 12 to 13% in either group remained opioid-free.
This isn’t evidence that buprenorphine is addictive in the way heroin is. It reflects the nature of opioid use disorder itself. The underlying condition doesn’t disappear when the medication stops, just as high blood pressure returns when you stop taking blood pressure medication. The brain changes driving opioid cravings can persist for months or years.
Research on what happens after people discontinue buprenorphine reinforces this point. A multi-site study tracking patients who stopped treatment found that those who discontinued after 91 to 180 days had nearly triple the risk of opioid overdose compared to those who stayed on treatment for more than a year. There was no treatment duration that eliminated the risk of death after stopping. This is a strong argument for longer, not shorter, courses of treatment.
Why the “Trading One Addiction for Another” Framing Is Misleading
Someone taking buprenorphine daily for opioid use disorder is physically dependent on the medication. They are not, in most cases, addicted to it. They’re not escalating doses to chase euphoria, crushing pills to inject them, or losing jobs and relationships because of buprenorphine use. They’re taking a stable dose that keeps cravings manageable and blocks the effects of other opioids.
The ceiling effect is central here. With full agonist opioids, taking more always produces a bigger high, which drives dose escalation and the spiral of addiction. With buprenorphine, taking more eventually stops producing additional effects. The pharmacology itself resists the escalation pattern that characterizes addiction.
People with diabetes don’t think of themselves as “addicted to insulin.” The framing of buprenorphine dependence as addiction has real consequences: it leads people to quit effective treatment prematurely, and it leads some clinicians to under-prescribe a medication with strong evidence behind it. Recent federal policy changes reflect growing recognition of this problem. As of early 2025, practitioners can prescribe an initial six-month supply of buprenorphine through telemedicine, including audio-only visits, removing barriers that previously made it harder to start and stay on treatment.
The Bottom Line on Risk
Buprenorphine carries real risks. You will become physically dependent. Withdrawal, while milder than with other opioids, is uncomfortable. A small percentage of people do misuse it. Combining it with benzodiazepines or alcohol can be dangerous.
But compared to the opioids it replaces, buprenorphine is in a different category. It produces less euphoria, has a built-in ceiling on its most dangerous effects, blocks other opioids from working, and causes milder withdrawal. For people with opioid use disorder, the risk of untreated addiction, including fatal overdose, is far greater than the risk of buprenorphine dependence.